| Document |
Document Title |
|
WO/2024/073734A2 |
Pharmacological or genetic inactivation of MAGL reduces neuroinflammation and neuropathology in animal models of AD. However, global inactivation of MAGL induces functional tolerance of CB1R, which reduces the effectiveness of pharmacoth...
|
|
WO/2024/071362A1 |
The present invention addresses the problem of providing a new method for improving the delivery efficiency of a drug such as a nucleic acid drug to the nervous system. Provided is a delivery enhancer for enhancing the delivery of a dr...
|
|
WO/2024/065995A1 |
The present invention belongs to the technical field of detection, and particularly relates to a method, system and kit for in-situ detection of extracellular vesicle-carried miRNA. The present invention provides a method for in-situ det...
|
|
WO/2024/067192A1 |
A linear displacement isothermal amplification (LDIA) method and use thereof are provided. Specifically, an initial reaction of LDIA is started for four common primers of a template, including a pair of outer primers (LOF and LOR) and a ...
|
|
WO/2024/073386A1 |
An implantable medical device is provided. The implantable medical device includes a core having an antisense oligonucleotide (ASO) dispersed within a core polymer matrix. The core polymer matrix includes an ethylene vinyl acetate copoly...
|
|
WO/2024/068995A1 |
The invention relates to a novel functional transposase system. More specifically, the invention relates to a DNA transposon comprising a heterologous polynucleotide flanked by transposon flanking regions and to a recombinant transposase...
|
|
WO/2024/067222A1 |
CD3-targeting antibodies and bispecific antibodies targeting both CD3 and tumor-associated antigens. Polynucleotides encoding the antibodies, pharmaceutical compositions comprising the antibodies, and methods of producing the antibodies ...
|
|
WO/2024/071112A1 |
The present invention provides a method for producing an antibody comprising a combination of a VL domain and a VH domain having high affinity with respect to an antigen. The present invention pertains to a method comprising: setting mul...
|
|
WO/2024/068997A2 |
The present invention relates to antisense oligonucleotides (oligomers) complementary to NAT8L pre-mRNA and mRNA and which are capable of inhibiting the expression of NAT8L. Inhibition of NAT8L expression is beneficial for the treatment ...
|
|
WO/2024/012435A9 |
The present disclosure generally relates to gene editing systems and methods for treating hereditary angioedema (HAE). Also disclosed are polynucleotides, vectors, cells, kits and compositions comprising the components of the gene editin...
|
|
WO/2024/071970A1 |
The present invention relates to: a fusion polypeptide comprising a His tag, and a peptide tag of which the main amino acids are charged amino acids; a fusion protein in which the fusion polypeptide and a target protein are fused; and a ...
|
|
WO/2024/067876A1 |
The present invention generally relates to novel anti-FGFR2b antibodies and antigen-binding fragments thereof, which specifically bind fibroblast growth factor receptor 2b (FGFR2IIIb, or FGFR2b), and polynucleotides, vectors, cells, comp...
|
|
WO/2024/070874A1 |
The purpose of the present invention is to provide a monoclonal antibody that binds to A1 beta-casein or to both A1 beta-casein and A2 beta-casein and to provide a method for detecting A1 beta-casein using said monoclonal antibody. The m...
|
|
WO/2024/066120A1 |
Provided are a virus nucleic acid sample diluent, a virus nucleic acid sample extraction kit, and a virus nucleic acid extraction method. The provided virus nucleic acid sample release agent can be compatible with various sampling sets. ...
|
|
WO/2024/067451A1 |
The present invention provides an engineered extracellular vesicle, a pharmaceutical composition containing the engineered extracellular vesicle and a use thereof, and further provides a method for constructing the engineered extracellul...
|
|
WO/2024/067153A1 |
Provided are a nucleic acid for producing rAAV in an insect cell, a VP1 capsid protein mutant, and use. The nucleic acid comprises nucleotide sequences encoding adeno-associated viruses VP1, VP2, and VP3 proteins. Compared with the capsi...
|
|
WO/2024/070504A1 |
Provided is a blood storage composition which can prevent the contamination of a plasma layer with DNA derived from blood cells, and can prevent, compared to the amount of a plasma before storage, a decrease in the amount of a plasma aft...
|
|
WO/2024/071409A1 |
Provided are: a nucleic acid complex composition that has high efficiency for introducing nucleic acid molecules into cells and for diffusing the same within the cells and that can have high transfection efficiency; lipid particles for t...
|
|
WO/2024/070524A1 |
In a step for supplying a second coating solution (BB) in this cell tissue production method, when r1n (n being a natural number of 1≤n≤N) stands for the first size of each of N first coating solutions (AA), r2m (m being a natural nu...
|
|
WO/2024/068845A1 |
The invention relates to the field of genetic engineering and synthetic biology, more particularly to means and methods for facilitating genetic recombination. The application discloses novel Cre recombinase dependent recombination sites...
|
|
WO/2024/067151A1 |
Provided are an anti-respiratory syncytial virus (RSV) monoclonal antibody, a preparation method for the antibody, and related use of the antibody for immunodetection. The anti-RSV monoclonal antibody exhibits high sensitivity and high s...
|
|
WO/2024/073606A1 |
Methods for improving engraftment of donor cells in a subject thereof are provided. Such methods can comprise providing donor cells that have been modified to express a first isoform of a target protein (e.g., interleukin-2 receptor subu...
|
|
WO/2024/071375A1 |
The present invention addresses the problem of providing: a human astrocyte cell mass that is induced and differentiated from an astrocyte progenitor cell derived from a human iPS cell; a method for producing the human astrocyte cell mas...
|
|
WO/2024/067723A1 |
A respiratory syncytial virus subtype A (RSV-A) recombinant F protein, a polynucleotide, a nucleic acid construct, an expression vector, a host cell, a stabilized trimer formed by the recombinant F protein, an immunogenic composition com...
|
|
WO/2024/072929A1 |
The present disclosure provides a method of assessing translation efficacy of an mRNA using liquid chromatography-tandem mass spectrometry (LC-MS/MS). The mRNA is first translated into protein either in a cell lysate (cell-free translati...
|
|
WO/2023/039476A9 |
Described in several exemplary embodiments are compositions including a targeting moiety effective to target a central nervous system cell and formulations thereof. In certain embodiments, the targeting moiety is composed of one or more ...
|
|
WO/2024/073710A2 |
Systems and methods for activating immune cells are described. Immune cells can be activated using IgG bound with antigen or via light and light sensitive peptides. An immune cell can be genetically manipulated to express a light sensiti...
|
|
WO/2024/071134A1 |
The present invention addresses the problem of providing a mutant of a cyanobacterium having predation resistance. This problem is solved by a mutant of a cyanobacterium in which the function of the spoIID gene is reduced or defective co...
|
|
WO/2024/073744A2 |
The disclosure provides methods for promoting affinity maturation, and in particular in vivo affinity maturation, of antibodies. The disclosure also provides a system of affinity maturation of an antibody as well as compositions comprisi...
|
|
WO/2024/067885A1 |
Provided are novel antisense oligonucleotides ("ASOs") that generate or promote exon skipping during pre-mRNA splicing, pharmaceutical compositions containing such ASOs, and their use. ASOs (e.g., bipartite ASOs) comprise a targeting seq...
|
|
WO/2024/065070A1 |
A graph clustering-based genetic coding breeding prediction method and apparatus. The method comprises: constructing a genetic map on the basis of the gene-gene correlation strength; performing clustering solving on the genetic map to ob...
|
|
WO/2024/073697A1 |
The disclosure relates to Respiratory Syncytial Virus (RSV) vaccine compositions having truncated mucin domains in the G-protein. In certain embodiments, this disclosure relates to virus particles, virus-like particles, virosomes, nuclei...
|
|
WO/2024/073705A1 |
Provided herein are conjugated oligonucleotides that are characterized by efficient and specific eye distribution.
|
|
WO/2024/072958A1 |
The present invention relates to engineering synthetic major histocompatibility complex (MHC) molecules for generating universal peptide/MHC complexes with engineered disulfide linkage(s) using structure-guided modeling and design and me...
|
|
WO/2024/073404A1 |
Disclosed herein are transgenic non-human animal models of Pompe disease, methods of making, and methods of using the same. Disclosed herein are also nucleic acid molecules useful for making the non-human animal models of Pompe disease.
|
|
WO/2024/065041A1 |
The present disclosure relates to a sulfur-containing ionizable lipid or a pharmaceutically acceptable salt thereof that incorporates a dithioacetal or dithioketal moiety in one or more of its lipophilic chains. Further provided is a del...
|
|
WO/2024/071043A1 |
Provided is a novel production method of a hetero that enables the production of a heteromultimeric protein such as a bispecific antibody. The production method of the present disclosure, which is for producing a heteromultimeric prote...
|
|
WO/2024/064633A2 |
Compositions comprising an RNA molecule comprising a guide sequence portion having 17- 50 contiguous nucleotides containing nucleotides in the sequence set forth in any one of SEQ ID NOs: 1-6215 and methods and uses thereof.
|
|
WO/2024/064895A2 |
The present disclosure relates to adeno-associated virus (AAV)-mediated delivery of nucleic acids for treating neuromuscular disorders, e.g., X-linked myotubular myopathy (XLMTM), in patients in need thereof. The AAV vectors of the discl...
|
|
WO/2024/062417A1 |
The present disclosure relates to enzymes, compositions and methods for performing conditional homologous recombination of a targeted DNA molecule or genome by using modified proteins comprising nucleic acid DNA binding proteins with pro...
|
|
WO/2024/064192A1 |
Methods of treating a subject for a cellular proliferative disease, e.g., a cancer, are provided. Aspects of the methods include: administering to the subject an agent that modulates DSIF complex activity, e.g., activity of a DSIF comple...
|
|
WO/2024/064613A2 |
Compositions comprising an RNA molecule comprising a guide sequence portion having 17- 50 contiguous nucleotides containing nucleotides in the sequence set forth in any one of SEQ ID NOs: 1-7830 and methods and uses thereof.
|
|
WO/2024/064744A2 |
Engineered split dihydrofolate reductase-based methods and systems are provided for selecting cells that have stably acquired a heterologous polynucleotide.
|
|
WO/2024/064923A2 |
Disclosed herein are, inter alia, activators of K2P potassium channels and pharmaceutical compositions thereof, and methods comprising their use for the treatment of diseases or adverse conditions related to low TREK family protein activ...
|
|
WO/2024/064811A2 |
Provided are non-naturally occurring polynucleotide sequences that encode for polypeptides useful in ergoline biosynthesis, as well as the non-naturally occurring polypeptide sequences. Also provided are recombinant host cell and methods...
|
|
WO/2024/063036A1 |
The present invention pertains to a method and a kit for detecting the methylation of target DNA. Specifically provided is a method for detecting the methylation of target DNA, the method comprising: a step in which adaptor DNA including...
|
|
WO/2024/064782A2 |
Provided herein are recombinant adeno-associated virus (AAV) capsid proteins, compositions (e.g., rAAV) comprising the capsid proteins, nucleic acids encoding the capsid proteins, and methods of making and using the capsid proteins.
|
|
WO/2024/063050A1 |
Provided is a lipase variant having improved heterologous expression properties. This lipase variant comprises an amino acid sequence in which, in comparison to the amino acid sequence of the parent lipase, an amino acid residue that is ...
|
|
WO/2024/064771A1 |
Disclosed are anti-CD45 antibodies and anti-CD45 antibodies conjugated to IGN cytotoxins that specifically bind to human CD45. Such antibodies and ADCs are useful in therapeutic methods, including methods of depleting CD45+ cells from a ...
|
|
WO/2024/061356A1 |
The present invention provides an interfering RNA targeting microtubule protein β2 (TUBB2). The interfering RNA can reduce the expression of TUBB2, thereby treating a disease related to the increase of TUBB2 expression or excessive prol...
|
